Worth reading
79Important
Scored from 5 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
-539
¥100 million (year-on-year change in operating profit)Wording
Avoiding a definitive answer
How definitive the wording is.Contents of this document
Supplementary materials to the earnings reportSecond quarter of the fiscal year ending March 20267 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥2,665 100 million+17.3%
Operating profit¥423 100 million-56.0%
Ordinary income¥394 100 million -57.6%interim profit before tax
Net income¥382 100 million -61.3%interim profit attributable to owners of the parent
Selling, general and administrative expenses¥783 100 million
Results for the three months of the current quarter
Revenue
¥1,370 100 million
Core operating profit
¥240 100 million
Operating profit
¥241 100 million
Quarterly profit attributable to owners of the parent
¥212 100 million
Full-year earnings forecast
Revenue
¥5,650 100 million
Costs of sales
¥2,460 100 million
Gross profit
¥3,190 100 million
Selling, general and administrative expenses
¥1,640 100 million
Research and Development Expenses
¥520 100 million
Core operating profit
¥1,050 100 million
Operating profit
¥1,040 100 million
Profit for the period attributable to owners of the parent
¥940 100 million
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Regional breakdown
Japan51
United States48.7
Other52.3
Total49.4
Key products
Xeplion / Xeplion TRI48
Latuda53.3
Twymeeg55.1
Metgluco49.9
Authorized generic products53.1
Orgovyx51.7
Gemtesa61
Myfembree60.5
リサイミック (product)57.8
Aptiom47.1
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Revenue
Japan18
United States408
Other-32
Total394
Costs of sales338
Selling, general and administrative expenses44
Research and Development Expenses63
Other (within core)-489
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Assumed average JPY/USD exchange rate157
Foreign exchange sensitivity
Revenue¥2.9 billion for each ¥1 depreciation of the yen
Core operating profit¥700 million for each ¥1 depreciation of the yen
New initiatives
- Progress of new development products in the development pipeline
- Research and development of regenerative and cell therapies using iPS cells with RACTHERA and academic and industry partners
- Obtained conditional and time-limited approval in Japan for Amschepri (raguneprocel)
Key KPIsA metric the company considers important as a management benchmark.
- Overseas Revenue Mix83.2 %Year on year against the same period last yearUp from 81.3%
- Research and development expenses as a percentage of revenue8.9 %Year on year against the same period last yearUp from 7.7%
- ROE20.3 %Year on year against the same period last yearDown from 46.3%
- ROIC15.1 %Year on year against the same period last yearDown from 22.8%
Segment results
Japan
Revenue
¥446 100 million+4.2%
Gross profit
¥196 100 million
United States
Revenue
¥1,978 100 million+26.0%
Gross profit
¥1,197 100 million
Other
Revenue
¥241 100 million-11.8%
Gross profit
¥36 100 million
Financial targets
ROE
Actual results20.3 %
ROIC
Actual results15.1 %
Number of employees
30 September 2026
Consolidated3,135
Individual1,754
| Item | Details |
|---|---|
| Document type | Supplementary materials to the earnings report |
| Fiscal Period Covered | Second quarter of the fiscal year ending March 2026 |
| Net Sales | ¥2,665 100 million (YoY +17.3%) |
| Operating profit | ¥423 100 million (YoY -56.0%) |
| Ordinary income | ¥394 100 million (interim profit before tax) (YoY -57.6%) |
| Net income | ¥382 100 million (interim profit attributable to owners of the parent) (YoY -61.3%) |
| Selling, general and administrative expenses | ¥783 100 million |
| Results for the three months of the current quarter | Revenue ¥1,370 100 million / Core operating profit ¥240 100 million / Operating profit ¥241 100 million / Quarterly profit attributable to owners of the parent ¥212 100 million |
| Full-year earnings forecast | Revenue ¥5,650 100 million / Costs of sales ¥2,460 100 million / Gross profit ¥3,190 100 million / Selling, general and administrative expenses ¥1,640 100 million / Research and Development Expenses ¥520 100 million / Core operating profit ¥1,050 100 million / Operating profit ¥1,040 100 million / Profit for the period attributable to owners of the parent ¥940 100 million |
| Progress against full-year forecast | Regional breakdown Japan 51 / United States 48.7 / Other 52.3 / Total 49.4 / Key products Xeplion / Xeplion TRI 48 / Latuda 53.3 / Twymeeg 55.1 / Metgluco 49.9 / Authorized generic products 53.1 / Orgovyx 51.7 / Gemtesa 61 / Myfembree 60.5 / リサイミック (product) 57.8 / Aptiom 47.1 |
| Segment results | Japan Revenue ¥446 100 million (YoY +4.2%) / Gross profit ¥196 100 million / United States Revenue ¥1,978 100 million (YoY +26.0%) / Gross profit ¥1,197 100 million / Other Revenue ¥241 100 million (YoY -11.8%) / Gross profit ¥36 100 million |
| Breakdown of Factors Affecting the Change | Revenue Japan 18 / United States 408 / Other -32 / Total 394 / Costs of sales 338 / Selling, general and administrative expenses 44 / Research and Development Expenses 63 / Other (within core) -489 |
| Key KPIs | Indicator name Overseas Revenue Mix / Value 83.2 % / Year on year against the same period last year Up from 81.3%, Indicator name Research and development expenses as a percentage of revenue / Value 8.9 % / Year on year against the same period last year Up from 7.7%, Indicator name ROE / Value 20.3 % / Year on year against the same period last year Down from 46.3%, Indicator name ROIC / Value 15.1 % / Year on year against the same period last year Down from 22.8% |
| Number of employees | 30 September 2026 Consolidated 3,135 / Individual 1,754 / Change during the period Not disclosed / Hiring plan Not disclosed |
| Assumptions Underlying the Business Outlook | Assumed average JPY/USD exchange rate 157 / Foreign exchange sensitivity Revenue ¥2.9 billion for each ¥1 depreciation of the yen / Core operating profit ¥700 million for each ¥1 depreciation of the yen |
| Financial targets | ROE Actual results 20.3 % / ROIC Actual results 15.1 % |
| New initiatives | Progress of new development products in the development pipeline, Research and development of regenerative and cell therapies using iPS cells with RACTHERA and academic and industry partners, Obtained conditional and time-limited approval in Japan for Amschepri (raguneprocel) |
Items this document does not state (14)
Gross Profit MarginOperating profit marginSelf-assessment against the planUnit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookMedium-term management plan targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased by ¥40.8 billion in the United States, including a ¥16.7 billion impact from foreign exchange. On the profit side, the cost of sales increased by ¥33.8 billion, selling, general and administrative expenses by ¥4.4 billion, and research and development expenses by ¥6.3 billion, while other income included in core earnings decreased by ¥48.9 billion.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.